Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001563 · ClinicalTrials.gov registry record · Phase 2

EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma

A Phase 2 study of AIDS-Related Lymphoma and AIDS-Associated Lymphoma, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
39
Enrollment target
1
Study location

NCT00001563 is a Phase 2 study of AIDS-Related Lymphoma and AIDS-Associated Lymphoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 39 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001563, a Phase 2 study of AIDS-Related Lymphoma and AIDS-Associated Lymphoma, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
39 participants
Enrollment target
1
Study location

Study Summary

The prognosis of AIDS-related Non-Hodgkin's lymphoma is poor, especially in the relapsed setting. There is no standard treatment, and the few small studies that have been conducted have reported dismal outcomes. The purpose of this study is to pilot the use of EPOCH plus rituximab in previously treated AIDS-related lymphoma. Clinical endpoints of the study include toxicity and response. Progression-free and overall survival will be measured. Tumors will be evaluated for p53 mutations, p-16, bcl-2 expression, tumor proliferation, c-myc and EBV when possible.

Interventions

  • BIOLOGICAL Rituximab
  • BIOLOGICAL Filgrastim
  • DRUG EPOCH

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 1997-01-08
Est. Completion 2005-05-05
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00001563

The ClinicalTrials.gov registry entry for NCT00001563 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with AIDS-Related Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Rituximab is the first listed.

NCT00001563 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00001563 about?

NCT00001563 is a clinical study titled "EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma". The prognosis of AIDS-related Non-Hodgkin's lymphoma is poor, especially in the relapsed setting. There is no standard treatment, and the few small studies that have been conducted have reported dismal outcomes. The purpose of this study is to pilot the use of EPOCH plus rituximab in previously trea...

What is the current status of trial NCT00001563?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 1997-01-08. Estimated completion is 2005-05-05.

What conditions does trial NCT00001563 study?

This clinical trial studies the following conditions: AIDS-Related Lymphoma, AIDS-Associated Lymphoma.

What interventions are being tested in trial NCT00001563?

The interventions under investigation include: Rituximab (BIOLOGICAL), Filgrastim (BIOLOGICAL), EPOCH (DRUG).

Who is sponsoring clinical trial NCT00001563?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001563 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for AIDS-Related Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.